TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business UpdateGlobeNewsWire • 11/01/24
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple SclerosisGlobeNewsWire • 09/18/24
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of TreatmentGlobeNewsWire • 09/18/24
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingGlobeNewsWire • 09/05/24
TG Therapeutics Stock Jumps As Surprise Profit Smashes Views By 157%Investors Business Daily • 08/06/24
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/06/24
HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG TherapeuticsBusiness Wire • 08/06/24
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business UpdateGlobeNewsWire • 08/05/24
TG Therapeutics: Pressure On Briumvi To Perform As Share Price Hits ResistanceSeeking Alpha • 07/30/24
Stocks To Watch: Biotech Leader TG Therapeutics Clears Resistance AreaInvestors Business Daily • 06/26/24
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/07/24
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewsWire • 05/31/24
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewsWire • 05/28/24